Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1783 | Hydroxychloroquine + lopinavir/ritonavir Wiki | 0.58 |
| drug1879 | Icatibant Wiki | 0.58 |
| drug1541 | Five-days oseltamivir Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug868 | Cenicriviroc Wiki | 0.58 |
| drug2271 | Macrolide administered for 3-5 days Wiki | 0.58 |
| drug1544 | Fixed-duration Hydrocortisone Wiki | 0.58 |
| drug3952 | Ten-days oseltamivir Wiki | 0.58 |
| drug3056 | Prasugrel Wiki | 0.58 |
| drug3125 | Protocolised mechanical ventilation strategy Wiki | 0.58 |
| drug271 | Amoxicillin-clavulanate Wiki | 0.58 |
| drug1968 | Interferon-β1a Wiki | 0.58 |
| drug861 | Ceftaroline Wiki | 0.58 |
| drug4015 | Ticagrelor Wiki | 0.58 |
| drug2913 | Piperacillin-tazobactam Wiki | 0.58 |
| drug2272 | Macrolide administered for up to 14 days Wiki | 0.58 |
| drug3276 | Razuprotafib Wiki | 0.58 |
| drug2440 | Moxifloxacin or Levofloxacin Wiki | 0.58 |
| drug3615 | Shock-dependent hydrocortisone Wiki | 0.58 |
| drug862 | Ceftriaxone Wiki | 0.58 |
| drug1545 | Fixed-duration higher dose Hydrocortisone Wiki | 0.58 |
| drug1415 | Eritoran Wiki | 0.58 |
| drug3628 | Simvastatin Wiki | 0.41 |
| drug3989 | Therapeutic anticoagulation Wiki | 0.41 |
| drug942 | Clopidogrel Wiki | 0.33 |
| drug4401 | blood donation SMS Wiki | 0.33 |
| drug356 | Aspirin Wiki | 0.29 |
| drug3532 | Sarilumab Wiki | 0.26 |
| drug274 | Anakinra Wiki | 0.19 |
| drug2174 | Lopinavir/ritonavir Wiki | 0.18 |
| drug4249 | Vitamin C Wiki | 0.15 |
| drug1060 | Convalescent plasma Wiki | 0.12 |
| drug3738 | Standard of care Wiki | 0.11 |
| drug3319 | Remdesivir Wiki | 0.11 |
| drug4025 | Tocilizumab Wiki | 0.09 |
| drug1775 | Hydroxychloroquine Wiki | 0.06 |
| drug2916 | Placebo Wiki | 0.02 |
Navigate: Correlations HPO
There are 3 clinical trials
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Measure: Days alive and not receiving organ support in ICU Time: Day 21Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Measure: Health-related Quality of life assessment Time: 6 monthsDescription: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Measure: Destination at time of hospital discharge Time: Free text Day 90Description: Antibiotic Domain specific outcome
Measure: Occurrence of multi-resistant organism colonisation/infection Time: Day 90, censored at hospital dischargeDescription: Antibiotic Domain specific outcome
Measure: Occurrence clostridium difficile Time: Day 90, censored at hospital dischargeDescription: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.
Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death Time: Day 90, censored at hospital dischargeDescription: Antiviral Domain specific outcome. Only required at selected sites.
Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens Time: Day 3, up to Day 7Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint
Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing) Time: Day 90, censored at hospital dischargeThe goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Description: Time to achieve durable change in COVID-19 to ordinal level 4 or less for at least 48 hours
Measure: Identify agents that will result in substantial improvements to the clinical condition of participants with COVID-19 Time: Up to 28 daysDescription: % of COVID-19 level 5 who never progress to COVID-19 level 6/7
Measure: Improvement in disease severity Time: Up to 60 daysDescription: Ventilator-free Days
Measure: Health care utilization Time: Up to 60 daysDescription: Total grade 3 or higher AEs by arm and total number of patients with grade 3 or higher AEs by arm. ● Total grade 3 or higher AEs of special interest by arm and total number of patients with grade 3 or higher AEs of special interest by arms (based upon lab assessments)
Measure: Frequency of serious AEs Time: Up to 60 daysDescription: Mortality at 28 days after study enrollment
Measure: Mortality Time: Up to 28 daysThe primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
Description: Confirmed clinical recovery means the participant is fit for discharge from hospital. Fit for discharge is defined by achieving a score of 6, 7, or 8 on the 8-point ordinal scale of clinical severity status, without being re-hospitalized prior to Day 29. 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high-flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Time to confirmed clinical recovery Time: Up to Day 29Description: Oxygen-free recovery is defined as participants who are alive, discharged, and not receiving supplement oxygen
Measure: Number of participants who achieve oxygen-free recovery at Day 29 Time: Day 29Description: Fit for discharge is defined by achieving a score of 6, 7, or 8 on the 8-point ordinal scale of clinical severity status, without being re-hospitalized prior to Day 29. 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high-flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Number of participants who experience ≥2-point improvement from baseline or assessed as fit-for-discharge on the ordinal scale at Day 29 Time: Baseline to Day 29Description: 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Distribution of participants across the 8-point ordinal scale of clinical severity status scores at Day 8, Day 15 and Day 29 Time: Day 8, Day 15 and Day 29Description: 8-point ordinal scale of clinical severity status scores are: Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Worst post-baseline score on the 8-point ordinal scale of clinical severity status Time: Up to Day 29Description: Clinical recovery is defined by achieving a score of 6, 7 or 8 on the 8-point ordinal scale of clinical severity status. 8-point ordinal scale of clinical severity status scores are Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Number of participants who achieve clinical recovery at Day 8, Day 15, and Day 29 Time: Day 8, Day 15, and Day 29Description: Sustained clinical recovery is defined by achieving a score of 6, 7 or 8 on the 8-point ordinal scale of clinical severity status at follow-up visit (Day 60). 8-point ordinal scale of clinical severity status scores are Death Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) Hospitalized, on noninvasive ventilation or high flow oxygen devices Hospitalized, requiring supplemental oxygen Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care Not hospitalized, limitation on activities and/or requiring home oxygen Not hospitalized, no limitations on activities
Measure: Number of participants who achieve sustained clinical recovery at Day 60 Time: Day 60Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports